Sulfur-based compounds produced in our bodies help fight inflammation and create new blood vessels, among other ...

Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics, announced today the appointment of Karim Benhadji, M.D., as Chief Medical Officer, effective ...

The quest for VEGF and other factors that promote tumour angiogenesis was initiated many decades ago, and a long and complicated path has led to the development of inhibitors of these molecules as ...

Expert opinion from Matheus R Cerqueira Specialist in Family and Community Medicine · 7 years of experience · Brazil Diabetes ...

Expert opinion from Sai Kiran DonakantiMBB, DNB · 1 years of experience · IndiaType 2 diabetes, formerly known as adult onset ...

The firm is working with international and US partners to expand its validation data, with the goal of achieving IVD regulatory clearance across these markets.

NDAQ:MBRX) Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) ...

KSI-501 clinical program: In the first quarter of 2024 we shared the Phase 1 study results of KSI-501 in patients with diabetic macular edema ("DME") at the Angiogenesis, Exudation, and Degeneration ...

KSI-501 clinical program: In the first quarter of 2024 we shared the Phase 1 study results of KSI-501 in patients with diabetic macular edema ("DME") at the Angiogenesis, Exudation, and Degeneration ...

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics ...

The 17th World Congress on Polyphenols Applications which will be held on September 19-20, 2024 at Università degli Studi di ...